Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Novo Nordisk receives US FDA approval for Xultophy® 100/3.6

Novo Nordisk A/S
Posted on: 21 Nov 16

Bagsværd, Denmark, 21 November 2016 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Xultophy ® 100/3.6. Xultophy ® 100/3.6 is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily).

Xultophy ® 100/3.6, the approved brand name for IDegLira in the US, is a once-daily, single injection fixed combination of long-acting insulin degludec (Tresiba ® ) and the GLP-1 analogue liraglutide (Victoza ® ). In the DUAL phase 3 clinical trial programme, Xultophy ® 100/3.6 consistently showed an improvement of glycaemic control in adults with type 2 diabetes uncontrolled on liraglutide or basal insulin therapy. For adults inadequately controlled on insulin glargine U100, treatment with Xultophy ® 100/3.6 demonstrated a reduction in HbA 1c of 1.7% after 26 weeks. Xultophy ® 100/3.6 can be taken at the same time each day with or without food and will be available in a prefilled pen.

"We are pleased with the approval of Xultophy ® 100/3.6 and look forward to launching it in the US in the first half of 2017", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We believe Xultophy ® 100/3.6 offers significant benefits and is an important and convenient treatment option especially for people not achieving sufficient glycaemic control with basal insulin".

The approval follows the recommendation of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), which voted 16-0 in favour of an approval of Xultophy ® 100/3.6 for the treatment of adults with type 2 diabetes, at its meeting on 24 May 2016.

About Xultophy ® 100/3.6
Xultophy ® 100/3.6 is a once-daily, single injection fixed combination of long-acting insulin degludec (Tresiba ® ) and the GLP-1 analogue liraglutide (Victoza ® ). The Xultophy ® 100/3.6 pen delivers doses from 10 to 50 units with each injection. Each unit of Xultophy ® 100/3.6 contains 1 unit of insulin degludec and 0.036 mg of liraglutide.

Further information

Media:   
Katrine Sperling+45 3079 6718 krsp@novonordisk.com
Ken Inchausti (US)+1 609 786 8316 kiau@novonordisk.com
 

Investors:
  
Peter Hugreffe Ankersen+45 3075 9085 phak@novonordisk.com
Melanie Raouzeos+45 3075 3479 mrz@novonordisk.com
Hanna Ögren+45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen+45 3079 4461 armk@novonordisk.com
Kasper Veje (US)+1 609 235 8567 kpvj@novonordisk.com

Company announcement No 82 / 2016

PR161121_Xultophy_FDA_UK


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via GlobeNewswire
HUG#2058006
GlobeNewswire
globenewswire.com

Last updated on: 23/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.